These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 26068762)

  • 41. [Oesophageal and gastric pathology: early neoplastic lesions. case 2 and case 3. Dysplasia and superficial cancer on Barrett's oesophagus].
    Fléjou JF
    Ann Pathol; 2011 Oct; 31(5):363-8. PubMed ID: 21982243
    [No Abstract]   [Full Text] [Related]  

  • 42. Muscularis mucosae duplication and the musculo-fibrous anomaly in endoscopic mucosal resections for barrett esophagus: implications for staging of adenocarcinoma.
    Lewis JT; Wang KK; Abraham SC
    Am J Surg Pathol; 2008 Apr; 32(4):566-71. PubMed ID: 18300796
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fluorescence in situ hybridization identifies high risk Barrett's patients likely to develop esophageal adenocarcinoma.
    Brankley SM; Halling KC; Jenkins SM; Timmer MR; Iyer PG; Smyrk TC; Barr Fritcher EG; Voss JS; Kipp BR; Campion MB; Lutzke LS; Minot DM; Wang KK
    Dis Esophagus; 2016 Aug; 29(6):513-9. PubMed ID: 26043762
    [TBL] [Abstract][Full Text] [Related]  

  • 44. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report.
    Kimura H; Konishi K; Kaji M; Maeda K; Yabushita K; Miwa A
    Hepatogastroenterology; 2001; 48(42):1662-4. PubMed ID: 11813596
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus.
    Lord RV; Park JM; Wickramasinghe K; DeMeester SR; Oberg S; Salonga D; Singer J; Peters JH; Danenberg KD; Demeester TR; Danenberg PV
    J Thorac Cardiovasc Surg; 2003 Feb; 125(2):246-53. PubMed ID: 12579092
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The diagnosis and management of Barrett's esophagus.
    DeMeester SR; DeMeester TR
    Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinicopathologic and molecular analysis of high-grade dysplasia and early adenocarcinoma in short- versus long-segment Barrett esophagus.
    Nobukawa B; Abraham SC; Gill J; Heitmiller RF; Wu TT
    Hum Pathol; 2001 Apr; 32(4):447-54. PubMed ID: 11331963
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
    Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
    Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular markers and staging of early esophageal cancer.
    Hosch SB; Stoecklein NH; Izbicki JR
    Langenbecks Arch Surg; 2003 Apr; 388(2):77-82. PubMed ID: 12712339
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Allelic loss involving the tumor suppressor genes APC and MCC and expression of the APC protein in the development of dysplasia and carcinoma in Barrett esophagus.
    Bektas N; Donner A; Wirtz C; Heep H; Gabbert HE; Sarbia M
    Am J Clin Pathol; 2000 Dec; 114(6):890-5. PubMed ID: 11338478
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Letter to the editor regarding "Definition of Barrett's esophagus: time for a rethink-is intestinal metaplasia dead?".
    DeMeester SR
    Am J Gastroenterol; 2010 May; 105(5):1201-2; author reply 1202-3. PubMed ID: 20445513
    [No Abstract]   [Full Text] [Related]  

  • 52. Controversies in Barrett esophagus.
    Dunbar KB; Spechler SJ
    Mayo Clin Proc; 2014 Jul; 89(7):973-84. PubMed ID: 24867396
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
    Feith M; Stein HJ; Mueller J; Siewert JR
    Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
    [TBL] [Abstract][Full Text] [Related]  

  • 54. p53-mutant clones and field effects in Barrett's esophagus.
    Prevo LJ; Sanchez CA; Galipeau PC; Reid BJ
    Cancer Res; 1999 Oct; 59(19):4784-7. PubMed ID: 10519384
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pathology, Chemoprevention, and Preclinical Models for Target Validation in Barrett Esophagus.
    Urbanska AM; Ponnazhagan S; Mozafari M
    Cancer Res; 2018 Jul; 78(14):3747-3754. PubMed ID: 29959150
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association Between Germline Mutation in VSIG10L and Familial Barrett Neoplasia.
    Fecteau RE; Kong J; Kresak A; Brock W; Song Y; Fujioka H; Elston R; Willis JE; Lynch JP; Markowitz SD; Guda K; Chak A
    JAMA Oncol; 2016 Oct; 2(10):1333-1339. PubMed ID: 27467440
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Establishment and characterization of a bona fide Barrett esophagus-associated adenocarcinoma cell line.
    Alvarez H; Koorstra JB; Hong SM; Boonstra JJ; Dinjens WN; Foratiere AA; Wu TT; Montgomery E; Eshleman JR; Maitra A
    Cancer Biol Ther; 2008 Nov; 7(11):1753-5. PubMed ID: 18787394
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exploring the relationship between neutral and selective mutations in cancer.
    Maley CC; Forrest S
    Artif Life; 2000; 6(4):325-45. PubMed ID: 11348585
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular epigenomic subtypes of Barrett neoplasia.
    Meltzer SJ
    Nat Rev Gastroenterol Hepatol; 2020 May; 17(5):261-262. PubMed ID: 32214233
    [No Abstract]   [Full Text] [Related]  

  • 60. Surrogate Markers: Lessons from the Next Gen?
    Reid BJ
    Cancer Prev Res (Phila); 2016 Jul; 9(7):512-7. PubMed ID: 27138791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.